Vor Biopharma Past Earnings Performance
Past criteria checks 0/6
Vor Biopharma's earnings have been declining at an average annual rate of -37.5%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-37.5%
Earnings growth rate
67.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -78.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
Dec 05
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?
Aug 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
May 05Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?
Mar 13We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Oct 19Vor Bio appoints Eyal C. Attar as chief medical officer
Oct 12Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?
Jun 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Mar 05Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Aug 30Vor Biopharma: Targeted Therapies For Transplants
Jun 30We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
May 10Vor Biopharma EPS misses by $0.03
May 06Revenue & Expenses BreakdownBeta
How Vor Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -118 | 32 | 94 |
| 30 Sep 23 | 0 | -116 | 32 | 90 |
| 30 Jun 23 | 0 | -106 | 32 | 80 |
| 31 Mar 23 | 0 | -98 | 30 | 71 |
| 31 Dec 22 | 0 | -92 | 29 | 65 |
| 30 Sep 22 | 0 | -86 | 27 | 60 |
| 30 Jun 22 | 0 | -81 | 25 | 56 |
| 31 Mar 22 | 0 | -78 | 24 | 54 |
| 31 Dec 21 | 0 | -70 | 21 | 48 |
| 30 Sep 21 | 0 | -70 | 20 | 46 |
| 30 Jun 21 | 0 | -65 | 18 | 41 |
| 31 Mar 21 | 0 | -56 | 15 | 34 |
| 31 Dec 20 | 0 | -49 | 12 | 32 |
| 30 Sep 20 | 0 | -36 | 8 | 23 |
| 30 Jun 20 | 0 | -26 | 7 | 17 |
| 31 Mar 20 | 0 | -19 | 5 | 12 |
| 31 Dec 19 | 0 | -13 | 4 | 6 |
Quality Earnings: VOR is currently unprofitable.
Growing Profit Margin: VOR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VOR is unprofitable, and losses have increased over the past 5 years at a rate of 37.5% per year.
Accelerating Growth: Unable to compare VOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: VOR has a negative Return on Equity (-78.2%), as it is currently unprofitable.